• About us
• Contact

Advertisement

Organisation › Details

Casdin Capital LLC (Casdin Life Sciences Partners)

Casdin Capital, LLC is a New York-based research investment firm focused on the innovations currently reshaping life sciences and healthcare. Founded in 2011, and with an eye to long-term returns and disruptive technologies, Casdin Capital is a trusted investor-partner in both private and public companies, collaborating with industry leaders to fuel their visions, adding energy, insight, and experience to the firm’s over $3 billion under management. *

 

	Start	2011-01-01 established
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Casdin, Eli (Casdin Capital 202204 Chief Investment Officer + Founder)
	Person 2	Rodriguez, Shaun (Casdin Capital 202201 Director of Life Science Research)
	Region	New York, NY
	Country	United States (USA)
	Street	1350 Avenue of the Americas Suite 2405
	City	10019 New York, NY
	Tel	+1-212-897-5430
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	3,000,000,000 (capital under management (2022) 2022-04-01)
		* Document for »About Section«: Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA.
		Record changed: 2024-11-09

Advertisement

More documents for Casdin Capital LLC (Casdin Life Sciences Partners)

• [1] IDRx, Inc.. (8/2/22). "Press Release: IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies". Plymouth, MA....
• [2] Leyden Laboratories B.V.. (1/25/22). "Press Release: Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses". Amsterdam & Boston, MA....
• [3] Stilla Technologies SAS. (11/23/21). "Press Release: Stilla Technologies Secures Financing of more than €31 Million Adding Casdin Capital and the European Investment Bank to Existing Investors". Paris & Boston, MA....
• [4] Mnemo Therapeutics (FR). (6/16/21). "Press Release: Mnemo Therapeutics Announces €75 Million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform". Paris....
• [5] C2i Genomics, Inc.. (4/15/21). "Press Release: C2i Genomics Raises $100 Million to Commercialize the Detection of Tiny Traces of Cancer Using AI and Whole Genome Sequencing". New York, NY....
• [6] Leyden Laboratories B.V.. (3/25/21). "Press Release: Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital". Am...
• [7] SomaLogic, Inc.. (12/22/20). "Press Release: SomaLogic Adds $81M to Series A Financing Totaling $214M". Boulder, CO....
• [8] Bayer AG. (12/21/20). "Press Release: Bayer Sells a Facility at Its Wuppertal Site to WuXi Biologics". Wuppertal & Leverkusen....
• [9] DNA Script. (7/29/20). "Press Release: DNA Script Expands Series B to $89M". Paris & South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.